

ADHD - Non Stimulant Agents

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year
Quantity Limit	
All agents	May be subject to quantity limit
Medications	Comments
Atomoxetine	N/A
Clonidine (extended release)	N/A
Guanfacine (extended release)	N/A

Attention deficit hyperactivity disorder (ADHD) may also be referred to as attention deficit disorder (ADD).

APPROVAL CRITERIA

- I. Requests for guanfacine extended release, clonidine extended release, and atomoxetine may be approved if the following criteria are met:

- A. Individual is 6 years of age or older; **AND**
- B. Individual has a diagnosis of attention deficit hyperactivity disorder;

Requests for atomoxetine may not be approved for the following:

- A. Individual has a diagnosis of narrow angle glaucoma; **OR**
- B. Individual has a diagnosis of pheochromocytoma; **OR**
- C. Individual has severe cardiac or vascular disorders whose condition would be expected to deteriorate if they experience increases in blood pressure or heart rate that could be clinically important; for example, 15 to 20 mm Hg in blood pressure or 20 beats per minute in heart rate; **OR**
- D. Individual is a child or adolescent with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased risk due to noradrenergic effects; **OR**
- E. Individual is currently using a monoamine oxidase inhibitor (MAOI) or has used an MAOI in the previous 14 days; **OR**
- F. Individual has active liver disease as noted by jaundice or laboratory evidence of liver injury.

Atomoxetine has a black box warning for suicidal ideation in children and adolescents. Strattera was noted to increase the risk of suicidal ideation in short-term studies in children or adolescents with ADHD. The risk of use with the clinical need should be considered. Comorbidities occurring with ADHD may be associated with an increase in the risk of suicidal ideation and/or behavior. Individuals who are started on therapy should be monitored closely for suicidality (suicidal thinking and

behavior), clinical worsening, or unusual changes in behavior. Strattera is approved for ADHD in pediatric and adult individuals and not approved for major depressive disorder.

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2021. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: July 11, 2021.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2021; Updated periodically.
5. American Academy of Pediatrics. ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. *Pediatrics*. 2011; 128:1007-1022. Available from: <http://pediatrics.aappublications.org/content/128/5/1007.full.pdf>.
6. Wolraich ML, Hagen JF, Allan C, et al. AAP SUBCOMMITTEE ON CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVE DISORDER. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. *Pediatrics*. 2019;144(4):e20192528. Available at: <https://pediatrics.aappublications.org/content/pediatrics/144/4/e20192528.full.pdf>
7. Charach A, Dashti B, Carson P, et al. Attention Deficit Hyperactivity Disorder: Effectiveness of Treatment in At-Risk Preschoolers; Long-Term Effectiveness in All Ages; and Variability in Prevalence, Diagnosis, and Treatment. Comparative Effectiveness Review No. 44. (Prepared by the McMaster University Evidence-based Practice Center under Contract No. MME2202 290-02-0020.) AHRQ Publication No. 12-EHC003-EF. Rockville, MD: Agency for Healthcare Research and Quality. October 2011. Last Review July 2012. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm.
8. Post RE and Kurlansik SL. Diagnosis and Management of Attention-Deficit/Hyperactivity Disorder in Adults. *Am Fam Physician*. 2012; 85(9):890-896. Available from: <http://www.aafp.org/afp/2012/0501/p890.html>.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.